Applied DNA Sciences (NASDAQ:APDN), Inc. is a biotechnology company specializing in molecular-level authentication, supply chain traceability and anti-counterfeiting solutions. The company develops proprietary DNA-based markers and polymers that can be applied to products, packaging and raw materials to verify authenticity, deter counterfeiting and ensure chain-of-custody transparency. These technologies can be integrated into inks, textiles, plastics and other substrates, enabling clients to track and authenticate goods from manufacture through distribution and sale.
The company’s signature product lines include SigNature® DNA tracers, a molecular tagging system that embeds unique genetic codes into a wide range of materials, and the GenoLab® automated platform, which streamlines sample preparation and analysis. In addition to anti-counterfeiting and traceability services, Applied DNA Sciences offers environmental DNA (eDNA) testing, pathogen detection assays and custom polymer development for specialty applications. Customers span multiple industries, including apparel and footwear, pharmaceuticals, government and defense, oil and gas, agriculture and luxury goods.
Founded in 2003 and headquartered in Stony Brook, New York, with research and manufacturing facilities in Fort Lauderdale, Florida, Applied DNA Sciences has built a robust intellectual property portfolio covering synthetic biology, DNA chemistry and analytical methods. The company’s technologies have been adopted by leading global brands, government agencies and academic institutions to combat illicit trade, verify product authenticity and enhance laboratory workflows. Its services are offered worldwide through a network of strategic partners and direct sales channels.
Leadership is headed by President and Chief Executive Officer Todd R. Gaines, whose background in molecular diagnostics and life sciences commercialization guides the company’s strategic growth initiatives. Under Gaines’s tenure, Applied DNA Sciences has focused on expanding its product offerings, strengthening its patent estate and forging alliances with industry leaders to scale adoption of DNA-based authentication solutions. The company continues to invest in research and development to address emerging security needs and support seamless integration of its technologies into global supply chains.
